Skip to main content

Breast Cancer Research and Treatment

Ausgabe 3/2024

Inhalt (20 Artikel)

Open Access Review

Biomarkers predictive of a response to extended endocrine therapy in breast cancer: a systematic review and meta-analysis

Kirsten M. Woolpert, Thomas P. Ahern, Timothy L. Lash, Donna L. O’Malley, Alice M. Stokes, Deirdre P. Cronin-Fenton

Review

Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2- breast cancer

Dan Moldoveanu, Tanya L. Hoskin, Courtney N. Day, Amy K. Schulze, Matthew P. Goetz, Judy C. Boughey

Preclinical study

Olaparib enhances sensitization of BRCA-proficient breast cancer cells to x-rays and protons

Sohee Park, Changhoon Choi, Haeyoung Kim, Yong Jae Shin, Yunjeong Oh, Won Park, Won Kyung Cho, Nalee Kim

Open Access Clinical trial

Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study

Joanne L. Blum, Caroline DiCristo, David Gordon, Meghan S. Karuturi, David Oubre, Erin Jepsen, Juan Cuevas, Shailendra Lakhanpal, Monica Z. Montelongo, Zhe Zhang, Joseph C. Cappelleri, Yao Wang, Debu Tripathy

Clinical trial

Optimizing surgical strategy in locally advanced breast cancer: a comparative analysis between preoperative MRI and postoperative pathology after neoadjuvant chemotherapy

K. K. Rajan, C. Boersma, M. A. Beek, T. A. Berendsen, J. van der Starre-Gaal, M. van ’t Veer-ten Kate, A. B. Francken, E. M. Noorda

Clinical trial

Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer

M. Gaudio, F. Jacobs, C. Benvenuti, G. Saltalamacchia, R. Gerosa, R. De Sanctis, A. Santoro, A. Zambelli

Clinical Trial

The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study

Diogo Martins-Branco, Marie Kassapian, Véronique Debien, Rafael Caparica, Daniel Eiger, Urania Dafni, Charitini Andriakopoulou, Sarra El-Abed, Susan L. Ellard, Miguel Izquierdo, Malou Vicente, Saranya Chumsri, Martine Piccart-Gebhart, Alvaro Moreno-Aspitia, Ann Søegaard Knop, Janine Lombard, Evandro de Azambuja

Clinical trial

Positive predictive value of axillary lymph node cortical thickness and nodal, clinical, and tumor characteristics in newly diagnosed breast cancer patients

Anne-Sophie T. Loonis, Allyson L. Chesebro, Camden P. Bay, Leah H. Portnow, Anna Weiss, Sona A. Chikarmane, Catherine S. Giess

Epidemiology

European quality indicators developed by the European Commission Initiative on Breast Cancer: a first nationwide assessment for the Dutch setting

Kay Schreuder, Tim J. Bult, Babet Stroop, Linetta B. Koppert, Rhodé M. Bijlsma, Enja J. Bantema-Joppe, Marije J. Hoornweg, Sabine Siesling

Epidemiology

Risk of contralateral breast cancer among Asian/Pacific Islander women in the United States

Hsiao-Ching Huang, Jenny S. Guadamuz, Kent F. Hoskins, Naomi Y. Ko, Gregory S. Calip

Epidemiology

Secretory breast carcinoma: clinicopathological features and prognosis of 52 patients

Yuan-Yuan Zhao, Hui-Juan Ge, Wen-Tao Yang, Zhi-Ming Shao, Shuang Hao

Epidemiology

Racial/ethnic disparities in the association between patient care experiences and receipt of initial surgical breast cancer care: findings from SEER-CAHPS

Mariana Arevalo, Trevor A. Pickering, Sally W. Vernon, Kayo Fujimoto, Melissa F. Peskin, Albert J. Farias

Epidemiology

Assessment of breast cancer chemotherapy dose reduction in an integrated healthcare delivery system

Elizabeth D. Kantor, Kelli O’Connell, Isaac J. Ergas, Emily Valice, Janise M. Roh, Jenna Bhimani, Narre Heon, Jennifer J. Griggs, Jean Lee, Erin JA Bowles, Donna R. Rivera, Tatjana Kolevska, Elisa V Bandera, Lawrence H Kushi

Open Access Epidemiology

Individual and area level factors associated with the breast cancer diagnostic-treatment interval in Queensland, Australia

James D. Retell, Jessica K. Cameron, Joanne F. Aitken, Philippa Youl, Chris Pyke, Jeff Dunn, Suzanne Chambers, Peter D. Baade

Epidemiology

A new methodology to predict the oncotype scores based on clinico-pathological data with similar tumor profiles

Zeina Al Masry, Romain Pic, Clément Dombry, Chrisine Devalland

Original Laboratory Investigation

Screening mammographic performance by race and age in the National Mammography Database: 29,479,665 screening mammograms from 13,181,241 women

Cindy S. Lee, Lenka Goldman, Lars J. Grimm, Ivy Xinyue Liu, Michael Simanowith, Robert Rosenberg, Margarita Zuley, Linda Moy

Open Access Original Laboratory Investigation

Palbociclib sensitizes ER-positive breast cancer cells to fulvestrant by promoting the ubiquitin-mediated degradation of ER-α via SNHG17/Hippo-YAP axis

Lei Lei, Yuan Huang, Lei Shi, Weiwu Ye, Xianmei Lv, Lisha Ying, Xingfei Yu, Skye Hung-Chun Cheng, Yabing Zheng

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.